Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological malignancies such as relapsed/refractory acute B-cell lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Since 2017, six commercial CAR-T products have received FDA approval, with many more candidates advancing through the clinical pipeline1.   Despite its promise, the current manufacturing […]